Lonza Group is a Swiss global pharmaceutical, biotechnology, and nutrition manufacturing corporation based in Basel, with main operations in Europe, North America, and South Asia. Lonza was founded in Switzerland in the late nineteenth century. The company offers product development services to the pharmaceutical and biologic sectors, including bespoke manufacture of biopharmaceuticals and detection systems, as well as bioscience-related services.

Lonza collaborates with various pharmaceutical companies to manufacture biologics. In 2009, Lonza collaborated with Teva to research and produce biosimilars. They signed an agreement with GlaxoSmithKline in 2010 to develop therapeutic monoclonal antibodies. Lonza signed an agreement with Bristol-Myers Squibb in 2014 to produce two biologic pharmaceuticals. Imbruvica for Pharmacyclics and Mydicar for Celladon are both manufactured by Lonza. Lonza signed a contract with Alexion in 2015 to build a new facility specialized to Alexion manufacture. Lonza and Sanofi collaborated in 2017 to build a new biologics manufacturing plant.

Moderna signed a manufacturing agreement with Lonza in May 2020 to produce its (mRNA-1273) COVID-19 vaccine active ingredient, with sterile production and fill-finish activities growing to 500 million doses beginning in 2021. The mRNA bulk vaccination production began in January 2021, shortly after Swiss Federal Councilor Alain Berset's official visit. Lonza Group is responsible for the global manufacture of two-thirds of the raw materials for the Moderna vaccine at facilities in the United States and Switzerland. In addition, the company has begun working with Altimmune Inc. to develop a nasal COVID-19 vaccine.

Founded: 1897

Headquarters: Basel, Switzerland

Website: https://www.lonza.com/

Genmab is a Danish biotech firm that focuses on developing novel antibody-based therapies for cancer and other disorders. Since its founding in 1999, the business has solidified its position as a pioneer in the biotech sector by placing a priority on research and development.

A variety of cutting-edge cancer medicines, including monoclonal antibodies and bispecific antibodies, are available in the company's product pipeline. Additionally, Genmab is dedicated to creating new platforms and technologies for the identification and creation of novel therapeutics.

The success of Genmab can be traced to its commitment to innovation as well as to its emphasis on quality and perfection. The business employs a talented group of scientists and researchers who put in endless effort to promote biotechnology and enhance the lives of patients.

With a reach throughout the globe and a reputation for excellence, Genmab is one of the biggest and most reputable biotech firms in Europe. Genmab is a name you can trust for cutting-edge solutions and unequaled support, whether you are a researcher, doctor, or other professional working in the biotech industry.

Founded: 1999

Headquarters: Copenhagen, Denmark

Website: https://www.genmab.com/

BioNTech SE (short for Biopharmaceutical New Technologies) is a Mainz-based German biotechnology firm that develops and manufactures active immunotherapies for patient-specific approaches to illness treatment. It creates pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as personalized cancer immunotherapies, vaccines against infectious diseases, and protein replacement therapies for rare diseases, as well as engineered cell therapy, novel antibodies, and small molecule immunomodulators for cancer treatment.

To deliver individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing method, the business has developed an mRNA-based human therapeutic for intravenous injection.

In 2020, BioNTech, in collaboration with Pfizer for testing and logistics, produced the RNA vaccine BNT162b2 for preventing COVID-19 infections, which had a 91% efficacy at the time in preventing proven COVID-19 infections occurring at least 7 days after the second dose of vaccine. The United Kingdom government granted interim HMR authorization for BNT162b2 vaccinations within the United Kingdom on December 2, 2020. It was the first mRNA vaccination to be approved. The vaccine was given emergency permission in the United States, Canada, and Switzerland a few days later.

The European Commission authorized BioNTech/Pfizer's coronavirus vaccine on December 21, 2020, based on the European Medicines Agency's (EMA) favourable recommendation.

Founded: 2008

Headquarters: Mainz, Germany

Website: https://www.biontech.com/de/de/home.html

Argenx has developed an innovative approach to antibody engineering. The biotechnology company medication development pipeline includes antibody treatments for cancer as well as inflammatory and autoimmune illnesses.

Argenx released positive phase III data for their lead drug candidate efgartigimod in the year 2020. These results demonstrated that the medicine had alleviated the motor symptoms of patients who were living with the autoimmune condition myasthenia gravis.

Efgartigimod's authorisation application is now being reviewed by regulatory authorities in Europe, the United States of America, and Japan; the results of this evaluation are anticipated to be available in the middle of 2022. Argenx is traded on both the Euronext and the Nasdaq in the United States.

Founded: 2008
Headquarters: Breda, Netherlands
Website: https://www.argenx.com/

bioMérieux SA is an international biotechnology company that was established in Marcy-l'Étoile, France, in close proximity to Lyon. Its headquarters are located there. bioMérieux has a physical presence in 44 countries and, through its extensive distribution network, serves more than 160 more nations.

diagnostic solutions, including reagents, devices, software, and services, are provided by bioMérieux. These solutions pinpoint the source of disease and contamination in order to enhance patient health and protect consumer safety. Its products are utilized for a variety of diagnostic applications, including monitoring and screening for cancer, infectious diseases, and cardiovascular emergencies. Microorganisms in agri-food, medicinal, and cosmetic products can also be identified with their help using these tests.

bioMérieux is a publicly traded company that can be found under the ticker symbol "BIM" and the ISIN number "FR0013280286."

By the year 2020, bioMérieux had generated revenues of €3.1 billion, with 93% of sales coming from locations other than France.

Founded: 1963

Headquarters: Marcy-l'Étoile, France

Website: https://www.biomerieux.com/

Qiagen is a leading biotech company based in Germany, with a global presence and a focus on developing innovative solutions for life science research and diagnostic applications. Qiagen is trusted by academics, clinicians, and other biotech experts after 35 years in the sector.

The company offers DNA and RNA sample preparation, genotyping, gene expression analysis, and other technologies. Qiagen also develops innovative molecular diagnostics assays for infectious illnesses and cancer.

Qiagen's success is due to its innovation and client service. To stay ahead in biotech, the company invests extensively in R&D and collaborates with top academic institutions and other partners.

Qiagen's commitment to innovation, quality, and customer service has made it one of Europe's largest and most prestigious biotech firms with a global reach. Qiagen provides cutting-edge technologies and unmatched support for biotech researchers, clinicians, and other professionals.

Founded: 1984

Headquarters: Venlo, Netherlands

Website: https://www.qiagen.com/

Ipsen is a biopharmaceutical business with its headquarters in Paris, France. The company focuses on developing breakthrough treatments in the fields of oncology, rare disease, and neuroscience. Regarding sales in the cancer sector, Ipsen is among the top 15 biopharmaceutical companies in the world.

Ipsen was established in 1929 by Henri Beaufour, and the company currently has over 5000 people across the globe. Ipsen's pharmaceuticals have been granted registration in over one hundred countries, and the company has a direct commercial presence in over thirty of those nations. Ipsen is comprised of 3 pharmaceutical research centers and 4 worldwide R&D hubs located all over the world.

Ipsen has been run by the same family for the past ninety years, and the company is currently listed on the Euronext Paris stock exchange as a component of the SBF 120 index (2005). Two of the Beaufour family members, Anne Beaufour and Henri Beaufour, serve on the company's board of directors. The Beaufour family holds 57% of the company's shares and 73% of its voting rights.

Founded: 1929

Headquarters: Boulogne-Billancourt, France

Website: https://www.ipsen.com/

Bachem Holding AG is a biotechnology business based in Switzerland that operates in the areas of chemistry, biochemistry, and pharmaceuticals.

Bachem specializes in the creation of peptide-based biochemicals as well as the development of manufacturing procedures for these compounds, as well as the commercial manufacture of peptides and complex organic compounds as active medicinal components.

It is a wholly owned subsidiary of Ingro Finanz AG and was established in 1971. The headquarters are located in Bubendorf, which is in the canton of Basel-Landschaft. Production facilities are located in Vionnaz, which is in the canton of Valais, as well as in the cities of Vista and Torrance in the state of California, as well as in St. Helens, which is close to Liverpool, in Great Britain. Sales and distribution are handled out of Tokyo.

Bachem had 1057 workers, revenue of CHF 261.6 million, and a net income of CHF 41.8 million as of the end of 2017.

Founded: 1971

Headquarters: Bubendorf, Switzerland

Website: https://www.bachem.com/

Swedish Orphan Biovitrum (Sobi) is a leading biotech business focusing on rare diseases, a global presence, and scientific innovation, making it a key player in the healthcare market.

Sobi focuses on researching and developing medicines for rare diseases, with a particular emphasis on hemophilia, inflammation, and genetic and metabolic problems. They are committed to making a difference in the lives of patients suffering from these disorders, which frequently have few therapeutic alternatives.

Sobi has offices throughout Europe, North America, and the Middle East. They work with healthcare providers, patient organizations, and other stakeholders worldwide to further their purpose of enhancing patients' lives.

Sobi's R&D efforts are focused on finding novel medicines for rare diseases by using cutting-edge technology and scientific methodologies. The company has a proven track record of developing innovative products, including numerous authorized therapies for uncommon disorders.

Sobi is committed to sustainability and social responsibility and has implemented many efforts to reduce its environmental footprint while supporting community development and education. In keeping with their firm beliefs, they try to create a beneficial influence beyond healthcare.

Founded: 2001

Headquarters: Stockholm, Sweden

Website: https://www.sobi.com/

Orion Corporation is a leading biotech business situated in Finland that specializes in the discovery and production of novel medications, active pharmaceutical components, and diagnostic testing. With an emphasis on research and development, Orion Corporation has earned a reputation for scientific innovative excellence, making them one of Europe's largest biotech corporations.

The company's research efforts are focused on a variety of therapeutic areas, including neurological illnesses, oncology, and respiratory ailments. Orion Corporation has a team of skilled scientists and researchers dedicated to developing novel solutions that can enhance the lives of patients.

The commitment of Orion Corporation to environmental responsibility and sustainability is equally remarkable. Various initiatives have been implemented by the company to reduce its environmental impact and promote sustainable practices, demonstrating its commitment to making a positive impact beyond healthcare.

Orion Corporation's devotion to scientific innovation, patient care, and environmental responsibility has elevated them to the forefront of the biotech sector, prepared to continue pushing advancement and make a real difference in the lives of people around the world.

Founded: 1917

Headquarters: Espoo, Finland

Website: https://www.orion.fi/

Roivant Sciences is a pharmaceutical business that uses technology to produce drugs. Roivant creates biotech and healthcare technology subsidiaries.

Roivant Sciences was formed in 2014 by Vivek Ramaswamy. Ramaswamy's initial plan was to in-license drug candidates and form subsidiaries focused on specific therapeutic areas, intending to align incentives and boost capital efficiency. This strategy has evolved to incorporate the development of earlier stage medication candidates and platform technologies. Roivant is the parent company of over a dozen subsidiaries, including Immunovant, a majority-owned public firm focused on autoimmune illnesses, and Dermavant Sciences, a privately held commercial-stage startup focused on medical dermatology.

Roivant Health, a business branch of Roivant, also develops healthcare technologies. Roivant created and released Datavant, which assists healthcare organizations in securely sharing data, and was merged with Ciox to become a $7 billion corporation. Lokavant, which integrates clinical trial data to identify and manage risks in pharmaceutical development, is also part of Roivant's technological portfolio.

Founded: 2014

Headquarters: Basel, Switzerland

Website: https://www.roivant.com/

Grifols, headquartered in Barcelona, Spain, is one of Europe's major biotech companies, with a global presence in over 100 countries. Their dedication to creating life-saving plasma-derived products and services has propelled them to the forefront of transfusion medicine, clinical diagnostics, and hospital pharmacy.

Grifols is dedicated to making a beneficial impact beyond healthcare, undertaking various programs to lessen their environmental imprint and assist community development and education. Their commitment to sustainability and social responsibility is key to their company values.

Grifols has a century of experience and a reputation for innovation, quality, and patient care. Their plasma-derived products are used to treat a variety of medical conditions, such as immune deficiencies, bleeding disorders, and neurological disorders. Grifols is well-positioned to continue driving advancements in the healthcare business and make a meaningful difference in the lives of patients worldwide as a major participant in the biotech industry.

Founded: 1940

Headquarters: Barcelona, Spain

Website: https://www.grifols.com/

Tecan is one of the most significant companies in biotechnology based in Europe. The company offers laboratory automation products to customers in the life sciences industry and other applied areas. Tecan is a pioneer in the field of laboratory automation and a market leader with more than 40 years of expertise in the industry.

Solutions for genomics, proteomics, cell biology, liquid handling, and other areas are included in their comprehensive assortment of goods, which are both adaptable and scalable. Tecan's solutions are developed to assist scientists and researchers in accelerating the process of research and discovery while simultaneously improving the accuracy and reproducibility of their findings.

Tecan's most recent financial reports indicate that the company's trailing twelve-month revenue (TTM) totals 1.03 billion dollars. The company's revenue for the year 2021 was $1.03 billion, representing an increase from the previous year's revenue of $0.82 billion.

Tecan is the company to go with if you want trustworthy and cutting-edge solutions for automating your laboratory.

Founded: 1980

Headquarters: Männedorf, Switzerland

Website: https://www.tecan.com/

Ascendis Pharma is one of Europe's major biotech businesses, headquartered in Copenhagen, Denmark, with the purpose of improving patients' lives through creative drug development. Since its inception in 2007, the company has quickly evolved into a prominent participant in the biotech industry, operating in the United States and Germany.

The team at Ascendis Pharma is driven by a strong vision to make a significant difference in the lives of patients. They intend to accomplish this by developing best-in-class treatments that meet unmet medical needs and improve patient outcomes. The firm focuses on endocrine and metabolic illnesses, and their TransCon technology platform enables the creation of long-acting prodrug medicines with sustained and consistent dosing.

Numerous awards and industry recognition have recognized Ascendis Pharma's commitment to innovation and excellence. The company has a strong pipeline of medication candidates in various phases of research, including treatments for growth hormone insufficiency, achondroplasia, and hypoparathyroidism.

Ascendis Pharma is a premier biotech business that is transforming the healthcare industry. Its commitment to improve patient outcomes, as well as its unique approach to drug development, has positioned it as a prominent leader in the biotech industry, with a bright future ahead.

Founded: 2007

Headquarters: Hellerup, Denmark

Website: https://ascendispharma.com